📣 VC round data is live. Check it out!

Cellectis Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cellectis and similar public comparables like Vanda Pharmaceuticals, Newron Pharmaceuticals, Prelude Therapeutics, Elite Pharmaceuticals and more.

Cellectis Overview

About Cellectis

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.


Founded

2000

HQ

France

Employees

222

Financials (LTM)

Revenue: $73M
EBITDA: ($52M)

EV

$260M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cellectis Financials

Cellectis reported last 12-month revenue of $73M and negative EBITDA of ($52M).

In the same LTM period, Cellectis generated $73M in gross profit, ($52M) in EBITDA losses, and had net loss of ($90M).

Revenue (LTM)


Cellectis P&L

In the most recent fiscal year, Cellectis reported revenue of $79M and EBITDA of ($40M).

Cellectis is unprofitable as of last fiscal year, with gross margin of 80%, EBITDA margin of (50%), and net margin of (86%).

See analyst estimates for Cellectis
LTMLast FY202320242025202620272028
Revenue$73M$79M$755K$42M$73M
Gross Profit$73M$63M($7M)$32M$63M
Gross Margin100%80%(883%)78%87%
EBITDA($52M)($40M)($93M)($9M)($40M)
EBITDA Margin(71%)(50%)(12270%)(23%)(55%)
EBIT Margin(88%)(42%)(12888%)(143%)(45%)
Net Profit($90M)($68M)($101M)($37M)($68M)
Net Margin(124%)(86%)(13385%)(89%)(93%)

Financial data powered by Morningstar, Inc.

Cellectis Stock Performance

Cellectis has current market cap of $379M, and enterprise value of $260M.

Market Cap Evolution


Cellectis' stock price is $3.76.

Cellectis share price decreased by 3.2% in the last 30 days, and increased by 144.9% in the last year.

Cellectis has an EPS (earnings per share) of $-0.67.

See more trading valuation data for Cellectis
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$260M$379M-0.2%-3.2%-7.5%144.9%$-0.67

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cellectis Valuation Multiples

Cellectis trades at 3.6x EV/Revenue multiple, and (5.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Cellectis

EV / Revenue (LTM)


Cellectis Financial Valuation Multiples

As of May 13, 2026, Cellectis has market cap of $379M and EV of $260M.

Cellectis has a P/E ratio of (4.2x).

LTMLast FY202320242025202620272028
EV/Revenue3.6x3.3xn/m6.3x3.6x
EV/EBITDA(5.0x)(6.5x)(2.8x)(27.5x)(6.5x)
EV/EBIT(4.1x)(7.9x)(2.7x)(4.4x)(7.9x)
EV/Gross Profit3.6x4.1x(39.1x)8.1x4.1x
P/E(4.2x)(5.6x)(3.7x)(10.3x)(5.6x)
EV/FCF(2.1x)(6.1x)(10.1x)13.6x(6.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cellectis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cellectis Margins & Growth Rates

Cellectis decreased revenue by 22% but EBITDA grew by 82% in the last fiscal year.

In the most recent fiscal year, Cellectis reported gross margin of 80%, EBITDA margin of (50%), and net margin of (86%).

See estimated margins and future growth rates for Cellectis

Cellectis Margins

Last FY202420252026202720282029
Gross Margin80%78%87%100%
EBITDA Margin(50%)(23%)(55%)(118%)
EBIT Margin(42%)(143%)(45%)(146%)
Net Margin(86%)(89%)(93%)(181%)
FCF Margin(54%)46%(59%)(220%)

Cellectis Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(22%)5397%76%(16%)
Gross Profit Growth(3%)(585%)95%(3%)
EBITDA Growth82%(90%)321%81%
EBIT Growth172%(39%)(44%)172%
Net Profit Growth65%(64%)84%65%
FCF Growth215%(174%)(324%)215%

Data powered by FactSet, Inc. and Morningstar, Inc.

Cellectis Operational KPIs

Cellectis' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.

Cellectis' Rule of 40 is (133%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cellectis' Rule of X is (157%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cellectis
LTMLast FY202320242025202620272028
Rule of 40(57%)(133%)
Bessemer Rule of X(36%)(157%)
Revenue per Employee$0.4M
Opex per Employee$0.4M
G&A Expenses to Revenue11%1342%20%12%
R&D Expenses to Revenue138%119%11609%218%128%
Opex to Revenue122%12005%221%132%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Vanda Pharmaceuticals0.9x0.8x(1.3x)
Newron Pharmaceuticals17.5x16.0x(77.0x)(53.9x)
Prelude Therapeutics24.5x17.7x(2.9x)
Elite Pharmaceuticals4.3x126.4x
Silence Therapeutics541.6x173.5x(3.4x)(3.6x)
Racura Oncology780.7x(76.5x)
Shanghai Hile Bio-Tech11.7x(13.3x)
Renata1.5x10.6x

This data is available for Pro users. Sign up to see all Cellectis competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cellectis

When was Cellectis founded?Cellectis was founded in 2000.
Where is Cellectis headquartered?Cellectis is headquartered in France.
How many employees does Cellectis have?As of today, Cellectis has over 222 employees.
Who is the CEO of Cellectis?Cellectis' CEO is Andre Choulika.
Is Cellectis publicly listed?Yes, Cellectis is a public company listed on Euronext Paris.
What is the stock symbol of Cellectis?Cellectis trades under ALCLS ticker.
When did Cellectis go public?Cellectis went public in 2007.
Who are competitors of Cellectis?Cellectis main competitors include Vanda Pharmaceuticals, Newron Pharmaceuticals, Prelude Therapeutics, Elite Pharmaceuticals, Silence Therapeutics, Racura Oncology, Shanghai Hile Bio-Tech, Renata, Ourofino, Formycon.
What is the current market cap of Cellectis?Cellectis' current market cap is $379M.
What is the current revenue of Cellectis?Cellectis' last 12 months revenue is $73M.
What is the current revenue growth of Cellectis?Cellectis revenue growth (NTM/LTM) is 14%.
What is the current EV/Revenue multiple of Cellectis?Current revenue multiple of Cellectis is 3.6x.
Is Cellectis profitable?No, Cellectis is not profitable.
What is the current EBITDA of Cellectis?Cellectis has negative EBITDA and is not profitable.
What is Cellectis' EBITDA margin?Cellectis' last 12 months EBITDA margin is (71%).
What is the current EV/EBITDA multiple of Cellectis?Current EBITDA multiple of Cellectis is (5.0x).
What is the current FCF of Cellectis?Cellectis' last 12 months FCF is ($124M).
What is Cellectis' FCF margin?Cellectis' last 12 months FCF margin is (171%).
What is the current EV/FCF multiple of Cellectis?Current FCF multiple of Cellectis is (2.1x).
How many companies Cellectis has acquired to date?Cellectis hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Cellectis has invested to date?Cellectis hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cellectis

Lists including Cellectis

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial